XOMA Royalty (NASDAQ:XOMA) Shares Pass Above 200-Day Moving Average – Here’s What Happened

XOMA Royalty Corporation (NASDAQ:XOMA) shares passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $31.74 and traded as high as $41.92. XOMA Royalty shares last traded at $41.80, with a volume of 142,874 shares traded.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on XOMA shares. Zacks Research raised XOMA Royalty from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 8th. HC Wainwright lowered XOMA Royalty from a “buy” rating to a “neutral” rating and set a $39.00 price target for the company. in a research report on Thursday, April 30th. Benchmark lowered XOMA Royalty from a “buy” rating to a “hold” rating in a research report on Friday, May 22nd. Lucid Cap Mkts lowered XOMA Royalty from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 27th. Finally, TD Cowen raised XOMA Royalty to a “hold” rating in a research report on Friday, February 13th. One equities research analyst has rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, XOMA Royalty has an average rating of “Hold” and a consensus price target of $53.75.

XOMA Royalty Stock Up 0.1%

The company has a 50-day moving average of $40.04 and a 200-day moving average of $31.74. The company has a market capitalization of $524.21 million, a price-to-earnings ratio of 26.62 and a beta of 0.88. The company has a current ratio of 3.59, a quick ratio of 3.59 and a debt-to-equity ratio of 0.96.

XOMA Royalty (NASDAQ:XOMA) last announced its earnings results on Tuesday, May 12th. The biotechnology company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($0.02). XOMA Royalty had a net margin of 53.46% and a return on equity of 12.56%. The business had revenue of $12.32 million for the quarter, compared to analyst estimates of $13.91 million. On average, equities analysts predict that XOMA Royalty Corporation will post 0.9 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of XOMA. Woodline Partners LP increased its holdings in shares of XOMA Royalty by 7.9% in the first quarter. Woodline Partners LP now owns 168,550 shares of the biotechnology company’s stock valued at $3,359,000 after purchasing an additional 12,284 shares during the period. Geode Capital Management LLC increased its holdings in shares of XOMA Royalty by 9.1% in the second quarter. Geode Capital Management LLC now owns 203,601 shares of the biotechnology company’s stock valued at $5,132,000 after purchasing an additional 16,929 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of XOMA Royalty by 13.9% in the second quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock valued at $112,000 after purchasing an additional 543 shares during the period. Rhumbline Advisers increased its holdings in shares of XOMA Royalty by 18.0% in the second quarter. Rhumbline Advisers now owns 13,249 shares of the biotechnology company’s stock valued at $334,000 after purchasing an additional 2,019 shares during the period. Finally, Marshall Wace LLP increased its holdings in shares of XOMA Royalty by 12.2% in the second quarter. Marshall Wace LLP now owns 16,308 shares of the biotechnology company’s stock valued at $411,000 after purchasing an additional 1,775 shares during the period. 95.92% of the stock is owned by institutional investors and hedge funds.

XOMA Royalty Company Profile

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.